European Growth Leaders With Strong Insider Ownership

Amidst recent fluctuations in the European market, driven by geopolitical tensions and rising energy prices, investors are increasingly focused on companies that demonstrate resilience and potential for growth. In this environment, stocks with strong insider ownership often stand out as they suggest confidence from those closest to the company’s operations and strategic direction.

Top 10 Growth Companies With High Insider Ownership In Europe

Name	Insider Ownership	Earnings Growth
Pharma Mar (BME:PHM)	12.1%	39.6%
MilDef Group (OM:MILDEF)	10.3%	31.1%
Kuros Biosciences (SWX:KURN)	25.9%	58.6%
KebNi (OM:KEBNI B)	12%	103.8%
Gold Road International (OB:GOLDR)	35.9%	89.8%
CTT Systems (OM:CTT)	17.4%	55.3%
Clavister Holding AB (publ.) (OM:CLAV)	20.5%	60.7%
CD Projekt Red (WSE:CDR)	35.2%	43.4%
Bonesupport Holding (OM:BONEX)	10.6%	32.2%
Bergen Carbon Solutions (OB:BCS)	11.9%	52%

Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Egetis Therapeutics (OM:EGTX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Egetis Therapeutics AB is a pharmaceutical company focused on developing and commercializing orphan drugs in Sweden and internationally, with a market cap of SEK3.74 billion.

Operations: The company generates revenue primarily from its Emcitate segment, amounting to SEK66 million.

Insider Ownership: 18.4%

Revenue Growth Forecast: 36.5% p.a.

Egetis Therapeutics is poised for significant growth, with earnings projected to increase 55.56% annually and revenue expected to grow at 36.5% per year, outpacing the Swedish market. Despite past shareholder dilution and a low forecasted return on equity of 6.3%, insiders have been net buyers recently, albeit in modest volumes. The company trades significantly below its estimated fair value and aims for profitability within three years, bolstered by recent Orphan Drug Designation in Japan for Emcitate (tiratricol).

• Click here to discover the nuances of Egetis Therapeutics with our detailed analytical future growth report.
• Our valuation report here indicates Egetis Therapeutics may be overvalued.

Hacksaw (OM:HACK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hacksaw AB (publ) is a B2B technology platform and game development company operating in Sweden and the Czech Republic, with a market cap of SEK26.06 billion.

Operations: Hacksaw generates revenue by providing online casino solutions and related services to gaming operators, amounting to €224.01 million.

Insider Ownership: 13.2%

Revenue Growth Forecast: 20.3% p.a.

Hacksaw AB (publ) is expanding its Latin American presence through partnerships with Brazino777 and Caliente.mx, enhancing its reach in Brazil and Mexico. The company trades significantly below estimated fair value and forecasts suggest revenue growth of 20.3% annually, surpassing the Swedish market's decline. Earnings are projected to grow at 19.1% per year, supported by high-quality earnings and a very high forecasted return on equity of 90.8%.

• Unlock comprehensive insights into our analysis of Hacksaw stock in this growth report.
• Upon reviewing our latest valuation report, Hacksaw's share price might be too pessimistic.

AlzChem Group (XTRA:ACT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AlzChem Group AG, along with its subsidiaries, develops, produces, and markets a variety of chemical specialties across Germany, the European Union, other parts of Europe, Asia, the NAFTA region, and internationally; it has a market cap of €1.66 billion.

Operations: The company generates revenue primarily from its Specialty Chemicals segment, which accounts for €398.39 million, and its Basics & Intermediates segment, contributing €152.20 million.

Insider Ownership: 15.5%

Revenue Growth Forecast: 11.5% p.a.

AlzChem Group AG demonstrates growth potential with its earnings forecasted to increase by 19.6% annually, outpacing the German market's average. The company is trading significantly below its estimated fair value, suggesting possible undervaluation. Recent expansions include a new U.S. production facility in South Carolina, enhancing capacity in response to sustained demand and supporting long-term development. Despite slower revenue growth forecasts of 11.5% per year, AlzChem's strategic initiatives aim to strengthen its market position further.

• Click here and access our complete growth analysis report to understand the dynamics of AlzChem Group.
• In light of our recent valuation report, it seems possible that AlzChem Group is trading behind its estimated value.

Seize The Opportunity

• Click through to start exploring the rest of the 211 Fast Growing European Companies With High Insider Ownership now.
• Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com